Have you ever wondered where the data you provide are used?

Whether you are a participant in the study, or an NHS professional who provides the data to BSRBR-RA, the answer is the same. This data is vital in the ongoing research into the long-term safety of biologic, biosimilar and other targeted therapies for Rheumatoid Arthritis.

Over 20 years, there has been over 100 research papers published. Today, we are highlighting Lianne Kearsley-Fleet’s publication from 2023, which answered the question, Are biosimilars truly ‘similar’?

The analyses compared the etanercept originator with etanercept biosimilars in adults with Rheumatoid Arthritis. What was reassuring to both patients and clinical teams was that there were similar improvements to the arthritis regardless of the product taken.

You will find the lay summary of the publication on our website here. There is also an informative infographic available.

Related